Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 

Background

Tasha Francis, Ph.D. an associate in Fish & Richardson’s Twin Cities office, practices intellectual property litigation with an emphasis on patent litigation. Dr. Francis has represented plaintiffs and defendants in cases involving medical devices, biotechnology and pharmaceuticals. In addition, she writes extensively on topics related to the Biologics Price Competition and Innovation Act and life science Post-Grant proceedings. Dr. Francis is licensed to practice law in the state of Minnesota and before the United State Patent and Trademark Office.

Since joining Fish, Dr. Francis has been at the forefront of developing local programming with the Girl Scouts where local troops earn their Inventor’s Badge and Intellectual Property Patch.  The aim of the program is to educate young women on the basic tenets of intellectual property law, specifically copyrights, trademarks, and patents.

Dr. Francis earned her Ph.D. in Chemical Biology from the University of Michigan in 2010, where her thesis focused on the development of small molecule anti-cancer therapeutics.  In 2013, Dr. Francis graduated from the University of Michigan Law School, where she was a contributing editor for the Michigan Telecommunications and Technology Law Review.  ​​

Education

J.D., University of Michigan Law School 2013


Ph.D., University of Michigan 2010
Chemical Biology
Phi Kappa Pi, Iota Sigma Pi


B.A., Dartmouth College 2002
Chemistry and Mathematics

Admissions

  • U.S. Patent and Trademark Office 2009
  • Minnesota 2013
  • U.S. District Court for the District of Minnesota

Memberships & Affiliations

​Federal Bar Association
Contributing Editor, Michigan Telecommunications and Technology Law Review​

Other Distinctions

Publications
FDA to Hold Public Meeting on Biosimilar User Fees, co-written with Rachel Bandli, Fish Litigation Blog (September 21, 2016).

Amgen Argues "Entire Balance of BPCIA" in Jeopardy unless Federal Circuit Overturns Discovery Ruling. co-written with Jenny Shmuel and Holly Chamberlain, Fish Litigation Blog (September 20, 2016).

The Dance Continues: Apotex Petitions the Supreme Court for Review, co-written with Jenny Shmuel and Will Orlady, Fish Litigation Blog (September 19, 2016).

Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars​​, co-written with Jenny Shmuel, Fish Litigation Blog (September 8, 2016). 

FDA Approves Sandoz’s Biosimilar of Enbrel​®​, co-written with Jenny Shmuel, Fish Litigation Blog (August 31, 2016). 

Amgen Can Enforce Notice of Commercial Marketing for Epogen​® Biosimilar​, co-written with Jenny Shmuel, Fish Litigation Blog (August 8, 2016). 

Amgen DJ to Compel Patent Dance Dismissed​, co-written with Jenny Shmuel, Fish Litigation Blog (July 26, 2016). 

Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotex, co-written with Jenny Shmuel and Alex Pechette, Fish Litigation Blog (June 14, 2016).

Notice of Commercialization Is Only Effective After FDA-Approval Regardless of Whether Parties Dance, co-written with Jenny Shmuel, Fish Litigation Blog (July 11, 2016).

You Can’t Patent Dance Your Way Out of Biosimilar Notice, co-written with Jenny Shmuel, Law360 (July 8, 2016).

Janssen Uses Manufacturing Info Obtained in BPCIA Litigation to Target Supplier, co-written with Jenny Shmuel and Alex Pechette, Fish Litigation Blog (June 17, 2016).

Amgen v. Sandoz—The Biosimilars Battle Continues, co-written with Jenny Shmuel and Sarah Jack, Fish Litigation Blog (June 15, 2016).

Live from the ACI Biosimilar Conference, Fish Litigation Blog (June 15, 2016).

Janssen Continues BPCIA Litigation Against Celltrion But Eyes New Target, co-written with Jenny Shmuel and Alex Pechette, Fish Litigation Blog (June 10, 2016).

Janssen Seeks Expedited Trial Following FDA Approval of Remicade Biosimilar, co-written with Jenny Shmuel, Fish Litigation Blog (April 13, 2016).

Spangenberg Finds Partner to Target Nucynta® Patent, Fish Post-Grant Alerts (January 28, 2016).

Will the Trans-Pacific Partnership Derail Biologics? co-written with Terry Mahn, Pharmaceutical Compliance Monitor (December 4, 2015).

Kyle Bass Group Gets PTAB To Review 4 Celgene Patents, Fish Post-Grant Alerts (October 28,2015).

First Bass IPR Instituted, Fish Post-Grant Alerts (October 8, 2015).

PTAB Denies Sanctions Against Bass, Fish Post-Grant Alerts (September 28, 2015).

Kyle Bass’ IPRs: Are You Next?, Fish Post-Grant Alerts (September 8, 2015).

Injunction Denied, Sandoz Cleared to Launch, Fish Litigation Blog (September 2, 2015).

BPCIA Dance Partners Request En Banc Rehearing and Amgen Seeks Temporary Injunction, Fish Litigation Blog (August 27, 2015).

PTAB Denies First Two Bass IPR Petitions, Fish Post-Grant Alerts (August 25, 2015).

Bass IPR Activity Heats Up in August, Fish Post-Grant Alerts (August 21, 2015).

Bass Opposes Sanctions and Defends His Actions at the PTAB, Fish Post-Grant Alerts (August 12, 2015).

Choose Your Court, co-written with Dorothy Whelan, Life Sciences Intellectual Property Review(July 23, 2015).

The Confusing and Often Contradictory World of Pleading Defenses and Counterclaims in Patent Cases, co-written with Conrad Gosen, IPO Daily News™ (June 25, 2015).

Celgene Seeks Sanctions Against Bass, Fish Post-Grant Alerts (June 11, 2015).

Kyle Bass Files Fifteenth IPR Petition, Fish Post-Grant Alerts (May 22, 2015).

Preparing for Biosimilar Litigation, Fish Litigation Blog (May 12, 2015).

Amgen v. Sandoz: To Dance or Not?Fish Litigation Blog (May 11, 2015).

Non-Practicing Entities as IPR Petitioners in BioPharma, Fish Post-Grant Alerts, Fish Litigation Blog (April 23, 2015).

Fish & Girl Scouts Collaboration, Fish Articles (April 14, 2015).

Patenting Orphan Drugs>, Fish Litigation Blog (January 30, 2015).

Limelight v. Akamai: A software case worthy of biotech’s attention, Fish Litigation Blog (April 29, 2014).

Lexicography may not override ordinary meaning in the absence of clear disclaimer, Fish Litigation Blog (February 26, 2014).

Fed. Cir. adopts more flexible standards for awarding attorneys’ fees, Fish Litigation Blog (January 13, 2014).

Francis, T.M., Continued employment as sufficient consideration for pre-invention assignment agreements. State Bar of Michigan IPLS Proceedings, 2014, 25, 1-5.

Francis, T.M., Target identification and validation of a novel family of anti-inflammatory 1,4-benzodiazepine-2,5-diones. Dissertations Abstracts International, 2010.

Nicolaou, K.C., Brenzovich, W.E., Bulger, P.G. and Francis, T.M., Synthesis of iso-epoxy-amphidinolide N and des-epoxy-caribenolide I Structures. Initial Forays. Org. & Biomol. Chem. 2006, 11, 2119.

Francis, T.M.; Sundberg, T.B.; Cleary, J.; Groendyke, T.; Opipari, A.W.; Glick, G.D. Identification of cytotoxic, T-cell-selective 1,4-benzodiazepine-2,5-diones. Bio. Org. Med. Chem. Lett. 2006, 16, 2432.

Zhou, J.; Zong, C.; Francis, T.M.; Braun, C.L. Radiative Exciplexes of 1,2,4,5-Tetracyanobenzene with Sterically Hindered Alkylbenzenes. J. Phys. Chem. A. 2003, 107, 8319-8326.

Zhou, J.; Findley, B.R.; Francis, T.M.; Nytko, E.A.; Braun, C.L. The Solution Dynamics of Photoinduced Geminate Radical Ion Pairs: Free Ion Formation. Chemical Physics Letters. 2002, 362, 63-71.

Bruckner, Christian; McCarthy, J.R.; Daniell, H.W.; Pendon, Z.D.; Ilagan, R.P.; Francis, T.M.; Ren, L.; Birge, R.R.; Frank, H.A. A Spectroscopic and Computational Study of the Singlet and Triplet Excited States of Synthetic -Functionalized Chlorins. Chemical Physics. 2003, 294, 285-303.

What's trending with Tasha

Filter by
Fish Litigation Blog
September 21, 2016
FDA to Hold Public Meeting on Biosimilar User Fees
FDA to Hold Public Meeting on Biosimilar User Fees
Authors: Rachel Bandli, Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
September 20, 2016
Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Ruling
Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Ruling
Authors: Holly Chamberlain, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
September 19, 2016
The Dance Continues: Apotex Petitions the Supreme Court for Review
The Dance Continues: Apotex Petitions the Supreme Court for Review
Authors: Will Orlady, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
September 8, 2016
Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars
Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
August 31, 2016
FDA Approves Sandoz's Biosimilar of Enbrel®
FDA Approves Sandoz's Biosimilar of Enbrel®
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
August 8, 2016
Amgen Can Enforce Notice of Commercial Marketing for Epogen® Biosimilar
Amgen Can Enforce Notice of Commercial Marketing for Epogen® Biosimilar
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
July 26, 2016
Amgen DJ to Compel Patent Dance Dismissed
Amgen DJ to Compel Patent Dance Dismissed
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Life Sciences
Fish Litigation Blog
July 14, 2016
Fall-Out from the Federal Circuit’s Decision in Amgen v. Apotex
Fall-Out from the Federal Circuit’s Decision in <i>Amgen v. Apotex</i>
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D., Alex Pechette
IP Litigation
Life Sciences
Fish Litigation Blog
July 11, 2016
Notice of Commercialization Is Only Effective After FDA-Approval Regardless of Whether Parties Dance
Notice of Commercialization Is Only Effective After FDA-Approval Regardless of Whether Parties Dance
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
Fish Litigation Blog
June 22, 2016
Amgen v. Sandoz SCOTUS Appeal on Hold Until October
<i>Amgen v. Sandoz</i> SCOTUS Appeal on Hold Until October
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D., Alex Pechette
IP Litigation
Life Sciences
Fish Litigation Blog
June 17, 2016
Janssen Uses Manufacturing Info Obtained in BPCIA Litigation to Target Supplier
Janssen Uses Manufacturing Info Obtained in BPCIA Litigation to Target Supplier
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D., Alex Pechette
IP Litigation
Life Sciences
News
August 31, 2016
Fish & Girl Scouts Collaboration
Articles
load more topics